# Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer

> **NCT01491971** · PHASE2 · COMPLETED · sponsor: **Ferring Pharmaceuticals** · enrollment: 76 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Degarelix

## Key facts

- **NCT ID:** NCT01491971
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2013-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01491971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01491971, "Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01491971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*